U.S. Markets open in 8 hrs 47 mins

Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares

CEO of Neurocrine Biosciences Inc (30-Year Financial, Insider Trades) Kevin Charles Gorman (insider trades) sold 80,000 shares of NBIX on 08/08/2019 at an average price of $95.31 a share. The total sale was $7.6 million.

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences Inc has a market cap of $8.96 billion; its shares were traded at around $97.85 with a P/E ratio of 752.64 and P/S ratio of 15.28. GuruFocus has detected 1 severe warning sign with Neurocrine Biosciences Inc. .

CEO Recent Trades:

  • CEO Kevin Charles Gorman sold 80,000 shares of NBIX stock on 08/08/2019 at the average price of $95.31. The price of the stock has increased by 2.66% since.

Directors and Officers Recent Trades:

  • Director Gary A Lyons sold 10,000 shares of NBIX stock on 07/30/2019 at the average price of $92.07. The price of the stock has increased by 6.28% since.
  • Chief Legal Officer Darin Lippoldt sold 15,831 shares of NBIX stock on 07/30/2019 at the average price of $92.13. The price of the stock has increased by 6.21% since.
  • Chief Research Officer Dimitri E. Grigoriadis sold 60,000 shares of NBIX stock on 07/30/2019 at the average price of $92.92. The price of the stock has increased by 5.31% since.
  • Chief Development Officer Haig P. Bozigian sold 44,356 shares of NBIX stock on 07/30/2019 at the average price of $92.77. The price of the stock has increased by 5.48% since.
  • Chief Development Officer Haig P. Bozigian sold 30,680 shares of NBIX stock on 07/15/2019 at the average price of $87.5. The price of the stock has increased by 11.83% since.

For the complete insider trading history of NBIX, click here

.This article first appeared on GuruFocus.